FDA Advisers Back Novavax Vaccine As New U.S. Option

The video discusses Novavax's COVID vaccine, its FDA authorization process, and its unique mechanism using a targeted protein to boost the immune system. It highlights the vaccine's potential appeal due to fewer side effects and easier storage compared to mRNA vaccines. The current COVID-19 situation, including case statistics and reinfection trends, is reviewed. Future vaccine developments and goals, such as nasal or oral vaccines, are also discussed, along with vaccination rates in the U.S.

What challenges are faced in vaccinating children under the age of five?

What is the expected effectiveness of the Pfizer vaccine for children under 5 against Omicron?